Active, not recruitingPhase 3NCT03462719
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Janssen Research & Development, LLC
- Principal Investigator
- Janssen Research & Development, LLC Clinical TrialJanssen Research & Development, LLC
- Intervention
- Ibrutinib(drug)
- Enrollment
- 211 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2029
Study locations (30)
- Norton Cancer Institute, Louisville, Kentucky, United States
- John Theurer Cancer Center, Hackensack, New Jersey, United States
- Novant Health, Charlotte, North Carolina, United States
- Institut - Jules Bordet, Anderlecht, Belgium
- ZNA Stuivenberg, Antwerp, Belgium
- Universitair Ziekenhuis Gent, Ghent, Belgium
- Virga Jessa Ziekenhuis, Hasselt, Belgium
- UZ Leuven Gasthuisberg, Leuven, Belgium
- Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
- Cross Cancer Institute, Edmonton, Alberta, Canada
- Juravinski Cancer Centre, Hamilton, Ontario, Canada
- The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada
- CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont, Montreal, Quebec, Canada
- Jewish General Hospital, Montreal, Quebec, Canada
- Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika, Brno, Czechia
- +15 more locations on ClinicalTrials.gov
Collaborators
Pharmacyclics LLC.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03462719 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn